Emfolin 25 mg+5 mg (Tablet)

Indications

• Adjunct to diet and exercise
• Improves glycemic control
• Type 2 diabetes mellitus

Pharmacology

• Inhibits DPP-4 enzyme
• Increases active incretin hormones
• Stimulates insulin release
• Reduces glucagon levels
• Inhibitor of Sodium-glucose co-transporter 2 (SGLT2)
• Reduces renal reabsorption of glucose
• Increases urinary glucose excretion

Dosage & Administration

• Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily
• Increased dose: 25 mg Empagliflozin and 5 mg Linagliptin once daily
• Assess renal function before initiating
• Do not initiate if eGFR is below 45 mL/min/1.73 m²
• Discontinue if eGFR falls below 45 ml/min/1.73 m²

Interaction

• Coadministration with diuretics
• Coadministration with Insulin or Insulin secretagogues
• Rifampin decreased Linagliptin exposure
• Increase in urinary glucose tests
• Interference with 1,5-anhydroglucitol (1,5-AG) Assay

Contraindications

• Severe renal impairment
• End-stage renal disease or dialysis
• Hypersensitivity reactions to Linagliptin
• Serious hypersensitivity reaction to Empagliflozin

Side Effects

• Pancreatitis
• Ketoacidosis
• Volume Depletion
• Urosepsis and Pyelonephritis
• Hypoglycemia with concomitant use with Insulin and Insulin Secretagogues
• Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene)
• Genital Mycotic Infections
• Hypersensitivity Reactions
• Severe and Disabling Arthralgia
• Bullous Pemphigoid
• Heart Failure

Pregnancy & Lactation

• Not recommended during second and third trimesters
• Limited available data in pregnant women
• Risks associated with poorly controlled diabetes in pregnancy

Precautions & Warnings

• Pancreatitis
• Hypotension
• Ketoacidosis
• Acute kidney injury and impairment in renal function
• Urosepsis and Pyelonephritis
• Hypoglycemia
• Genital Mycotic Infections
• Hypersensitivity
• Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene)
• Genital Mycotic Infections
• Heart Failure

Overdose Effects

• Contact Poison Control Center
• Supportive measures
• Removal of unabsorbed material
• Hemodialysis removal not studied

Therapeutic Class

• Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

• Store below 30°C
• Keep away from light and wet place
• Keep out of reach of children

Related Brands

• Emaglin-L 25 mg+5 mg (Tablet) - dbl-pharmaceuticals-ltd
• Emaglin-L 10 mg+5 mg (Tablet) - dbl-pharmaceuticals-ltd
• Glinta Plus 25 mg+5 mg (Tablet) - renata-limited
• Glinta Plus 10 mg+5 mg (Tablet) - renata-limited
• Emparol-L 25 mg+5 mg (Tablet) - drug-international-ltd